DURABLE EFFICACY AND LONG-TERM SAFETY WITH PELABRESIB PLUS RUXOLITINIB IN JAK INHIBITOR–NAÏVE MYELOFIBROSIS: 96-WEEK RESULTS FROM THE PHASE III MANIFEST-2 STUDY (SIE 2026) - Oct 6, 2026 - Abstract #DP096; Pres time: Sep 21, 2026; 07:00 PM - 08:00 PM; Location: AREA POSTER; P3 | "The safety profile remained man- ageable and comparable between arms. Combining BET and JAK inhibition may provide clinically meaningful benefits and potential disease modification in MF."
Clinical • P3 data • Hematological Disorders • Myelofibrosis
|
|
A. Lucchesi1; R. Rampal2; J. Mascarenhas3; S. Grosicki4; D. Chraniuk5; E. Abruzzese6; P. Bose7; A. Gerds8; F. Palandri9; V. Gupta10; S. E. Lee11; A. Kuykendall12; S. Oh13; A. Patriarca14; A. Alvarez-Larran15; D. Lavie16; M. Talpaz17; J. J. Kiladjian18; R. Mesa19; M. Wroclawska20; X. Li21; T. Lehmann20; H. Maier20; C. Harrison22; A. Vannucchi23
|